• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Kashyap Patel, MD: COA's Goals for Its Biosimilars Committee

Video

Kashyap Patel, MD, discusses the goals of the Community Oncology Alliance (COA) in forming its biosimilars committee.

Transcript:

Biosimilars are a totally new class of drug in the United States, and unlike generics, there's a complex science involved in developing biosimilars.

But there’s a tremendous knowledge gap between the providers. Multiple studies have shown that between 1 and 4 to 1 and 2 doctors are not familiar with the FDA pathway, which is 351(k) for the biosimilar.

So [the Community Oncology Alliance, COA] plays a central role in evaluating this knowledge gap and bridging that gap by bringing the evidence-based scientific education piece to all the stakeholders, which includes in patients, physicians, as well as providers.

Recent Videos
Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health.
Elena Wolff-Holz, MD.
Elena Wolff-Holz, MD, global head of clinical development at Biocon Biologics
Elena Wolff-Holz, MD
Travis Brewer, Texas Oncology
Josh Canavan, PharmD, head of pharmacy at RazorMetrics
Tiago Biachi, MD, PhD
Elie Bahou, MD, PhD
Steve Pickette, PharmD
Sophia Humphreys, PharmD
Related Content
© 2025 MJH Life Sciences

All rights reserved.